{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:14:27Z","timestamp":1753877667061,"version":"3.41.2"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pregnant persons with chronic health conditions often require pharmacotherapy to remain healthy. The Antiretroviral Pregnancy Registry is a prospective, international, voluntary, and exposure registry that collects information on antiretroviral (ARV) exposure; however, a minority of providers use the registry, leaving critical gaps to guide prescribing in this population. The Task Force for the Elimination of Perinatal HIV Transmission in the United States, funded by the Centers for Disease Control and Prevention, has identified the monitoring of ARV safety as a paramount concern in the ongoing mission to eliminate perinatal human immunodeficiency virus (HIV) transmission. As active members of this task force, we urge all healthcare providers who care for pregnant individuals to prioritize reporting all ARV exposures to the registry.<\/jats:p>","DOI":"10.1093\/ofid\/ofae423","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T02:14:54Z","timestamp":1721441694000},"source":"Crossref","is-referenced-by-count":1,"title":["Safety of Antiretroviral Exposure During Pregnancy: Opportunities to Close Data Gaps"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4225-8336","authenticated-orcid":false,"given":"William R","family":"Short","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily S","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Alpert Medical School of Brown University , Providence, Rhode Island , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Simone","sequence":"additional","affiliation":[{"name":"Francois-Xavier Bagnoud Center, School of Nursing, Rutgers, The State University of New Jersey , Newark, New Jersey , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Statton","sequence":"additional","affiliation":[{"name":"Mother and Child Alliance , Chicago, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Finocchario-Kessler","sequence":"additional","affiliation":[{"name":"Department of Family Medicine & Community Health, University of Kansas Medical Center , Kansas City, Kansas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Lampe","sequence":"additional","affiliation":[{"name":"Division of HIV Prevention, National Center for HV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"2024082915075565700_ofae423-B1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1752-8062.2009.00079.x","article-title":"Pharmacotherapy and pregnancy: highlights from the first international conference for individualized pharmacotherapy in pregnancy","volume":"2","author":"Haas","year":"2009","journal-title":"Clin Transl Sci"},{"author":"Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission","key":"2024082915075565700_ofae423-B2","article-title":"Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States"},{"key":"2024082915075565700_ofae423-B3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/cid\/ciz121","article-title":"Importance of prospective studies in pregnant and breastfeeding women living with human immunodeficiency virus","volume":"69","author":"Colbers","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4 suppl","key":"2024082915075565700_ofae423-B4","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1542\/peds.113.S3.984","article-title":"Utilization of animal studies to determine the effects and human risks of environmental toxicants (drugs, chemicals, and physical agents)","volume":"113","author":"Brent","year":"2004","journal-title":"Pediatrics"},{"year":"2023","author":"Antiretroviral Pregnancy Registry Steering Committee","key":"2024082915075565700_ofae423-B5"},{"key":"2024082915075565700_ofae423-B6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11904-007-0020-y","article-title":"Teratogenicity risk of antiretroviral therapy in pregnancy","volume":"4","author":"Watts","year":"2007","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2024082915075565700_ofae423-B7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/archinte.162.3.355","article-title":"Periconceptional exposure to efavirenz and neural tube defects","volume":"162","author":"De Santis","year":"2002","journal-title":"Arch Intern Med"},{"key":"2024082915075565700_ofae423-B8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00002030-200201250-00025","article-title":"Myelomeningocele in a child with intrauterine exposure to efavirenz","volume":"16","author":"Fundar\u00f2","year":"2002","journal-title":"AIDS"},{"issue":"suppl 2","key":"2024082915075565700_ofae423-B9","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/QAD.0000000000000231","article-title":"Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis","volume":"28","author":"Ford","year":"2014","journal-title":"AIDS"},{"author":"Zash","key":"2024082915075565700_ofae423-B10"},{"key":"2024082915075565700_ofae423-B11","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1056\/NEJMc1807653","article-title":"Neural-tube defects with dolutegravir treatment from the time of conception","volume":"379","author":"Zash","year":"2018","journal-title":"N Engl J Med"},{"volume-title":"Neural tube defects and major external structural abnormalities by antiretroviral treatment regimen in Botswana: 2014-2022","author":"Zash","key":"2024082915075565700_ofae423-B12"},{"key":"2024082915075565700_ofae423-B13","doi-asserted-by":"crossref","first-page":"ofad441","DOI":"10.1093\/ofid\/ofad441","article-title":"Strengthening the evidence: similar rates of neural tube defects among deliveries regardless of maternal HIV status and dolutegravir exposure in hospital birth surveillance in Eswatini","volume":"10","author":"Gill","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024082915075565700_ofae423-B14","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S2352-3018(23)00108-X","article-title":"Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008\u201320: a national cohort study","volume":"10","author":"Kourtis","year":"2023","journal-title":"Lancet HIV"},{"author":"CityMatCH","key":"2024082915075565700_ofae423-B15"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae423\/58623395\/ofae423.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/8\/ofae423\/58875051\/ofae423.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/8\/ofae423\/58875051\/ofae423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T20:55:19Z","timestamp":1724964919000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae423\/7718714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,7,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae423","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,23]]},"article-number":"ofae423"}}